Report Detail

This report covers market size and forecasts of Remicade (infliximab) Drug, including the following market information:
Global Remicade (infliximab) Drug Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Remicade (infliximab) Drug Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Remicade (infliximab) Drug Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Remicade (infliximab) Drug Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

Key market players
Major competitors identified in this market include Janssen, Hospira, Celltrion Healthcare, Epirus Biopharmaceuticals, Samsung Bioepsis, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
Brands Drugs
Generic Drugs

Based on the Application:
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Pediatric Ulcerative Colitis
Other


  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Remicade (infliximab) Drug Industry
  • 1.7 COVID-19 Impact: Remicade (infliximab) Drug Market Trends
  • 2 Global Remicade (infliximab) Drug Quarterly Market Size Analysis

    • 2.1 Remicade (infliximab) Drug Business Impact Assessment - COVID-19
      • 2.1.1 Global Remicade (infliximab) Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Remicade (infliximab) Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Remicade (infliximab) Drug Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Remicade (infliximab) Drug Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Remicade (infliximab) Drug Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Remicade (infliximab) Drug Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Remicade (infliximab) Drug Market
    • 3.5 Key Manufacturers Remicade (infliximab) Drug Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Remicade (infliximab) Drug Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Brands Drugs
      • 1.4.2 Generic Drugs
    • 4.2 By Type, Global Remicade (infliximab) Drug Market Size, 2019-2021
      • 4.2.1 By Type, Global Remicade (infliximab) Drug Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Remicade (infliximab) Drug Price, 2020-2021

    5 Impact of Covid-19 on Remicade (infliximab) Drug Segments, By Application

    • 5.1 Overview
      • 5.5.1 Crohn's Disease
      • 5.5.2 Pediatric Crohn's Disease
      • 5.5.3 Ulcerative Colitis
      • 5.5.4 Pediatric Ulcerative Colitis
      • 5.5.5 Other
    • 5.2 By Application, Global Remicade (infliximab) Drug Market Size, 2019-2021
      • 5.2.1 By Application, Global Remicade (infliximab) Drug Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Remicade (infliximab) Drug Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Janssen
      • 7.1.1 Janssen Business Overview
      • 7.1.2 Janssen Remicade (infliximab) Drug Quarterly Production and Revenue, 2020
      • 7.1.3 Janssen Remicade (infliximab) Drug Product Introduction
      • 7.1.4 Janssen Response to COVID-19 and Related Developments
    • 7.2 Hospira
      • 7.2.1 Hospira Business Overview
      • 7.2.2 Hospira Remicade (infliximab) Drug Quarterly Production and Revenue, 2020
      • 7.2.3 Hospira Remicade (infliximab) Drug Product Introduction
      • 7.2.4 Hospira Response to COVID-19 and Related Developments
    • 7.3 Celltrion Healthcare
      • 7.3.1 Celltrion Healthcare Business Overview
      • 7.3.2 Celltrion Healthcare Remicade (infliximab) Drug Quarterly Production and Revenue, 2020
      • 7.3.3 Celltrion Healthcare Remicade (infliximab) Drug Product Introduction
      • 7.3.4 Celltrion Healthcare Response to COVID-19 and Related Developments
    • 7.4 Epirus Biopharmaceuticals
      • 7.4.1 Epirus Biopharmaceuticals Business Overview
      • 7.4.2 Epirus Biopharmaceuticals Remicade (infliximab) Drug Quarterly Production and Revenue, 2020
      • 7.4.3 Epirus Biopharmaceuticals Remicade (infliximab) Drug Product Introduction
      • 7.4.4 Epirus Biopharmaceuticals Response to COVID-19 and Related Developments
    • 7.5 Samsung Bioepsis
      • 7.5.1 Samsung Bioepsis Business Overview
      • 7.5.2 Samsung Bioepsis Remicade (infliximab) Drug Quarterly Production and Revenue, 2020
      • 7.5.3 Samsung Bioepsis Remicade (infliximab) Drug Product Introduction
      • 7.5.4 Samsung Bioepsis Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Remicade (infliximab) Drug Supply Chain Analysis
      • 8.1.1 Remicade (infliximab) Drug Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Remicade (infliximab) Drug Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Remicade (infliximab) Drug Distribution Channels
      • 8.2.2 Covid-19 Impact on Remicade (infliximab) Drug Distribution Channels
      • 8.2.3 Remicade (infliximab) Drug Distributors
    • 8.3 Remicade (infliximab) Drug Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      Summary:
      Get latest Market Research Reports on Remicade (infliximab) Drug. Industry analysis & Market Report on Remicade (infliximab) Drug is a syndicated market report, published as Global (United States, European Union and China) Remicade (infliximab) Drug Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Remicade (infliximab) Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,250.00
      $4,875.00
      $6,500.00
      2,551.25
      3,826.88
      5,102.50
      3,025.75
      4,538.63
      6,051.50
      510,607.50
      765,911.25
      1,021,215.00
      271,700.00
      407,550.00
      543,400.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report